The US FDA's monitoring of medical meetings has turned up another drug promotion violation, this time an exhibit of an investigational new drug being developed by Arog Pharmaceuticals Inc. for the treatment of acute myeloid leukemia (AML).
The agency sent Arog a June 28
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?